Denali Therapeutics (DNLI) Return on Invested Capital (2022 - 2023)
Denali Therapeutics (DNLI) posted quarterly Return on Invested Capital of 0.33% for Q3 2023, up 58.0% year-over-year from 0.21% in Q3 2022, and down 18.51% quarter-over-quarter from 0.28% in Q2 2023.
Denali Therapeutics (DNLI) Return on Invested Capital (2022 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has reported Return on Invested Capital for 2 consecutive years, with 0.33% the latest figure, recorded in Q3 2023.
- In Q3 2023, Return on Invested Capital rose 58.0% year-over-year to 0.33%; the TTM figure through Sep 2023 stood at 0.33% (up 58.0% YoY), while the FY2025 annual figure was 0.74%, changed N/A from the prior year.
- Return on Invested Capital eased to 0.33% in Q3 2023 per DNLI's latest filing, from 0.28% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.28% in Q2 2023 and bottomed at 1.07% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -0.33% |
| Jun 30, 2023 | -0.28% |
| Dec 31, 2022 | -0.54% |
| Sep 30, 2022 | -0.91% |
| Jun 30, 2022 | -1.07% |